Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Japan IP High Court Upholds Invalidation of Key Trazenta Dosage Patent
A closely watched appeal over a core secondary patent for the DPP-4 inhibitor Trazenta (linagliptin) has come down in favor of generic manufacturers, potentially clearing what experts describe as the biggest remaining legal hurdle to copycat entry. On February 9,…
To read the full story
Related Article
- Generic Entry into DPP-4 Class Poised to Accelerate in 2026
January 7, 2026
BUSINESS
- Padcev-Keytruda Gets FDA Priority Review for Cisplatin-Eligible Perioperative MIBC
April 22, 2026
- Pfizer’s Tukysa Makes Japan Debut for HER2-Positive Breast Cancer
April 22, 2026
- Novartis Japan Chief Urges Pro-Innovation Policies to Sustain Investments
April 21, 2026
- Samsca Generics Extend Label to ADPKD
April 21, 2026
- ASKA Ups Stake in MedChoice Parent to Deepen Philippines Tie-Up
April 21, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…